CTRB1 antibody - middle region (ARP33837_P050)
- Known as:
- CTRB1 (anti-) - middle region (ARP33837_P050)
- Catalog number:
- arp33837_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- CTRB1 antibody - middle region (ARP33837_P050)
Related genes to: CTRB1 antibody - middle region (ARP33837_P050)
- Gene:
- CTRB1 NIH gene
- Name:
- chymotrypsinogen B1
- Previous symbol:
- CTRB
- Synonyms:
- -
- Chromosome:
- 16q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2014-11-19
Related products to: CTRB1 antibody - middle region (ARP33837_P050)
Related articles to: CTRB1 antibody - middle region (ARP33837_P050)
- Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) is a widely used organophosphorus flame retardant that has raised growing concern because it is persistent, can bioaccumulate, and is toxic. However, its possible role in chronic kidney disease (CKD) is still not well understood. - Source: PubMed
Publication date: 2026/01/29
Zuo XuleiWang WeiHou XiaoyuZhang CongZhang YuxiZhang Juan - Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert cardiometabolic benefits beyond weight loss, yet their systemic proteomic mechanisms remain incompletely defined. We profiled short-term liraglutide-induced protein changes and compared them with published semaglutide signatures. - Source: PubMed
Publication date: 2026/01/07
Stefanakis KonstantinosGutierrez de Piñeres ValeriaVeeragandham PreethiMantzoros Christos S - Interindividual variability in the efficacy of various glucose-lowering drugs has been previously reported and partly explained by genetic variants. The aim of this review was to summarize currently available information on pharmacogenetic studies of the efficacy of incretin-based therapies such as glucagon-like peptide 1 (GLP-1) receptor agonists (GLP1RA) and dipeptidyl peptidase 4 (DPP-4i) inhibitors. Several missense variants of the GLP1R gene have been associated with the effects of GLP1RA or DPP-4 inhibitors on glycaemic compensation or weight. Pharmacogenetic effects have also been reported for several type 2 diabetes-associated loci, such as TCF7L2, THADA, MTNR1B, CDKAL1, KCNQ1, KCNJ11, and PAM in candidate gene approach studies. Genome-wide pharmacogenetic studies have identified new genes with potentially relevant pharmacogenetic effects (CTRB1/2, ARRB1, PRKD1). Although none of these genetic associations are currently used in guiding the treatment choices in clinical practice, they offer valuable insights bringing us a little closer to precision medicine. - Source: PubMed
Publication date: 2025/12/31
Yaluri Alena StančákováÜrgeová AnnaMaršálek MichalJavorský MartinTkáč Ivan - Marek's disease virus (MDV) is a highly contagious oncogenic alphaherpesvirus that continues to threaten global poultry production, highlighting the need for next-generation vaccines. Although in ovo delivery of conventional MDV vaccines has been effective, vaccine leakiness has accelerated viral evolution by promoting the selection of more virulent, immune-evasive strains. mRNA vaccines offer a flexible and rapidly adaptable platform capable of inducing potent immune responses, yet their application against MDV remains unexplored in the in ovo context. Here, we report the first in ovo administration of a bivalent MDV mRNA vaccine encoding glycoprotein B (gB) and phosphoprotein 38 (pp38). RNA sequencing of the spleen and bursa of Fabricius at 12-, 24-, and 48-hours post-vaccination revealed distinct, time- and tissue-specific transcriptional programs. In the spleen, differential expression analysis (fold-change ≥ 2, padj < 0.05) demonstrated early activation of caudal-type homeobox 1 (CDX1) and signal transducer and activator of transcription 1 (STAT1), together with interferon-stimulated antiviral genes MX dynamin-like GTPase 1 (MX1), 2'-5'-oligoadenylate synthetase-like (OASL), and interferon-induced protein with tetratricopeptide repeats 5 (IFIT5). In contrast, the bursa exhibited persistent modulation of colipase (CLPS), chymotrypsinogen B1 (CTRB1), and deoxyribonuclease I (DNASE1), indicating metabolic and apoptotic remodeling. These results demonstrate that in ovo mRNA vaccination against MDV rapidly activates organ-specific immune and metabolic pathways, providing a transcriptomic framework for the rational design of poultry mRNA vaccines. - Source: PubMed
Publication date: 2025/12/26
Shoja Doost JananYitbarek AlexanderWootton Sarah KBehboudi ShahriarSharif Shayan - Observational studies have suggested a potential association between autoimmune diseases and anemia, but the direction of causality remains unclear. To investigate the potential causal relationship between autoimmune diseases and anemia using Mendelian randomization (MR). - Source: PubMed
Publication date: 2025/11/12
Zhuang XinPan Tianen